Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.08% is 40% below its 5-year average of 3.45%, near the low end of its 5-year range (0.00%–7.39%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.02% below its 12-month average of 2.15%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.08%.
DEBT TO ASSETS RATIO
2.08%
DEBT TO ASSETS RATIO AVG TTM
2.15%
DEBT TO ASSETS RATIO AVG 3Y
2.54%
DEBT TO ASSETS RATIO AVG 5Y
3.45%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-3.02%
CURRENT VS 3Y AVG
-17.95%
CURRENT VS 5Y AVG
-39.64%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 739 covered companies
CURRENT VS SECTOR MEDIAN
+1983.06%
vs the sector median at left
Janux Therapeutics, Inc.
Market Cap
$1.05B
Debt to Assets Ratio
2.08%
TTM Avg
2.15%
3Y Avg
2.54%
5Y Avg
3.45%
Market Cap
$1.04B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03B
Debt to Assets Ratio
0.57%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.06B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Debt to Assets Ratio
0.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $1.05B | 2.08% | 2.15% | 2.54% | 3.45% |
| Immatics N.V. (IMTX)vs › | $1.04B | 0.03% | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | 0.07% | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.38% | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 0.57% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | 0.01% | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 0.54% | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 0.00% | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $996.94M | 0.01% | N/A | N/A | N/A |
Debt/Assets
2.1%
Debt/Equity
0.02
Current Ratio
16.35
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.08% |
| 2026-03-31 | 2.10% |
| 2025-12-31 | 2.20% |
| 2025-09-30 | 2.21% |
| 2025-06-30 | 2.15% |
| 2025-03-31 | 2.15% |
| 2024-12-31 | 2.17% |
| 2024-09-30 | 3.37% |
| 2024-06-30 | 3.45% |
| 2024-03-31 | 3.51% |
| 2023-12-31 | 6.45% |
| 2023-09-30 | 6.43% |
| 2023-06-30 | 7.39% |
| 2023-03-31 | 7.24% |
| 2022-12-31 | 6.95% |
| 2022-09-30 | 6.41% |
| 2022-06-30 | 6.06% |
| 2022-03-31 | 0.04% |
| 2021-12-31 | 0.05% |
| 2021-09-30 | 0.06% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
